SCHEMBL4200803

SCHEMBL4200803

CCOC(=O)c1nn2c(c1O)C(=O)N(C)CC2c1nc(C)cs1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.35
GABRA5 P31644 2/20 0.35
OPRM1 P35372 5/20 0.33
OPRK1 P41145 5/20 0.33
OGFRL1 Q5TC84 5/20 0.33
OPRD1 P41143 4/20 0.33
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33
CASP8 Q14790 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ADORA1 P30542 2/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199736 0.85 GABRA1 (0.36) GABRA1GABRA5OPRM1OPRK1OGFRL1
SCHEMBL4207843 0.83 MAPK1 (0.35) GABRA1GABRA5GABRG2GABRB3GABRA3
SCHEMBL4198619 0.69 MEN1 (0.36) GABRA1GABRA5GABRG2GABRB3GABRA3
SCHEMBL4198917 0.65 RIPK1 (0.40) KDM4EMAPT
SCHEMBL19773424 0.62 SMN1; SMN2 (0.39) KDM4EALDH1A1MAPTHSD17B10NPC1
SCHEMBL28492842 0.60 RIPK1 (0.47) KDM4EALDH1A1MAPTALOX12HSD17B10
SCHEMBL108390 0.59 MAPT (0.50) ALDH1A1MAPTHSD17B10NPC1RAB9A
SCHEMBL22277296 0.59 SMN1; SMN2 (0.53) CASP3CASP7CASP8NR1H2NR1H3
SCHEMBL20713807 0.59 SMN1; SMN2 (0.53) CASP3CASP7CASP8NR1H2NR1H3
SCHEMBL2589672 0.58 MAPT (0.42) KDM4EALDH1A1MAPTCASP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758585-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-07-22 EP disclosed
US-7476666-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-01-13 US disclosed
US-20080015187-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-17 US disclosed
EP-1758585-A2 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2007-03-07 EP disclosed
WO-2005120516-A2 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015187-A1 Hiv Integrase Inhibitors REV1, ZC3HAV1, PNP GABRA1 2247/4885GABRA5 2962/4885OPRM1 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.